Safrole oxide

Safrole oxide (112.36-449.44 μM; 24-48 h) reduces the viability of A549 human lung cancer cells in a dose-dependent and time-dependent manner, with viability decreasing to 57.78% (24 h, 449.44 μM) and 12.62% (48 h, 449.44 μM) relative to control cells^[1].
Safrole oxide (112.36-449.44 μM; 24 h) induces chromatin condensation and nuclear fragmentation, hallmarks of apoptosis, in A549 human lung cancer cells following 24 hours of treatment at concentrations from 112.36 to 449.44 μM^[1].
Safrole oxide (449.44 μM; 48 h) does not induce necrosis in A549 human lung cancer cells after 48 hours of treatment, as indicated by unchanged LDH release relative to control cells^[1].
Safrole oxide (224.72 μM; 24-48 h) blocks A549 human lung cancer cells completely at G₁ phase and partly at G₂-M phase over 24 to 48 hours of treatment, preventing cell cycle progression and driving cells toward apoptosis^[1].
Safrole oxide (224.72 μM; 24 h) dramatically up-regulates P53 protein expression but does not affect H-Ras protein expression in A549 human lung cancer cells after 24 hours of treatment^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.